Search Medical Condition
Please enter condition
Please choose location from dropdown

Nazareth, Belgium Clinical Trials

A listing of Nazareth, Belgium clinical trials actively recruiting patients volunteers.

RESULTS

Found (277) clinical trials

A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care

In the majority of European countries, the primary management of chronic heart failure patients is performed by General Practitioners in collaboration with cardiologists (specialists). Previous studies have shown that many patients suffering from CHF do not receive optimal pharmacological and/or device treatment for their disease. An increase in natriuretic peptides ...

Phase

1.05 miles

Learn More »

Multicentre Observational Study Evaluating the Clinical Outcome of the H1 Ceramic Hip Resurfacing Arthroplasty

Investigation type: Premarket study to receive a CE marking, followed by post-marketing surveillance follow-up. Investigation design: Prospective, consecutive series, multicentre, observational study Investigation objectives: Primary: confirm the safety of the H1 hip resurfacing prosthesis by demonstrating non-inferiority of the H1 device in terms of survivorship. Secondary: demonstrate superiority of the ...

Phase N/A

3.44 miles

Learn More »

Absorbable Versus Permanent Mesh Fixation Trial in Laparoscopic Midline Ventral Hernia Repair

To compare the use of absorbable tackers versus permanent tack fixation using a polyester large pore mesh in laparoscopic midline ventral hernia repair in a multicenter (Belgian) prospective randomized single-blinded trial. All patients referred for elective midline ventral hernia repair should be assessed for eligibility and entered in a study ...

Phase

3.66 miles

Learn More »

International Pediatric Peritoneal Biopsy Study

Please see study protocol and http://www.pedpd.org http://4c-study.org

Phase N/A

4.27 miles

Learn More »

Phase 1/2 Study Exploring the Safety Tolerability and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.

Phase

6.01 miles

Learn More »

Task-oriented Upper Limb Training in MS

An adequate upper limb function is crucial to independently perform Activities of Daily Living (ADL). Persons with neurological diseases often experience upper limb dysfunction. Upper limb function in Multiple Sclerosis (MS) is highly prevalent, increasing with overall disability level, while the detrimental impact on ADL is higher than in stroke, ...

Phase

6.37 miles

Learn More »

Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients

Non-interventional, multicenter, prospective, European study to describe the effectiveness of trabectedin + PLD in the treatment of relapsed ovarian cancer (ROC) patients according to SmPC regardless of previous use of an antiangiogenic drug

Phase N/A

7.01 miles

Learn More »

A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

Phase

8.42 miles

Learn More »

Clinical Evaluation of the Infinity DBS System

The purpose of this post market study is to support the chronic clinical performance of the Infinity Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG), DBS leads, extensions and related system components.

Phase N/A

8.42 miles

Learn More »

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Participants with FLT3/ITD AML in first morphologic complete remission (CR1) undergoing allogeneic hematopoietic stem cell transplant (HCT) will be randomized to receive gilteritinib or placebo 30 to 90 days after HCT for a two year period. Participants will be stratified according to: 1) conditioning regimen intensity (myeloablative vs. reduced intensity/non-myeloablative), ...

Phase

8.42 miles

Learn More »